Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic bone marrow-derived mesenchymal stem cells (UTHealth Houston)
- Development stage
- Unknown
- Lead developer
- University of Texas Health Science Center at Houston
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This investigational cell therapy consists of allogeneic bone marrow-derived mesenchymal stem cells (allo-hMSCs) developed by The University of Texas Health Science Center at Houston (UTHealth Houston) for the treatment of idiopathic Parkinson's disease. The therapy is designed to leverage the immunomodulatory properties of mesenchymal stem cells to reduce neuroinflammation, which is a key driver of dopaminergic neuron loss in Parkinson's. Administered via repeat intravenous infusions, the therapy has been evaluated in a Phase 2 randomized, double-blind, placebo-controlled trial (NCT04506073) to assess its safety and potential as a disease-modifying treatment. The cells are believed to exert neuroprotective effects by modulating the immune response and creating a more favorable environment for neuronal survival.
- Other names
- allo-hMSCsallogeneic human bone marrow-derived mesenchymal stem cells
Beyond the preview
Go deeper on allogeneic bone marrow-derived mesenchymal stem cells (UTHealth Houston).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic bone marrow-derived mesenchymal stem cells (UTHealth Houston).